TORONTO, May 29, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE), a Canadian cannabis company focused on building the world’s largest indoor hydroponic cultivation and processing facility through its wholly owned subsidiary FV Pharma Inc. (“FV”), a Licensed Producer (“LP”) pursuant to the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), is pleased to announce the company has commenced trading publicly on the Canadian Securities Exchange (“CSE”) under the symbol “HUGE”.
Month: May 2018
VANCOUVER, British Columbia, May 25, 2018 (GLOBE NEWSWIRE) — Mission Ready Services Inc. (“Mission Ready” or the “Company”) (TSXV:MRS) announces that the Company proposes to change its name from Mission Ready Services Inc. to Mission Ready Solutions Inc.
CALGARY, May 2, 2018 /CNW/ – High Tide Ventures Inc. (“High Tide” or the “Company”) today announced that it has completed and closed a non-brokered private placement offering (the “Offering”), pursuant to which the Company issued 3,705,000 common shares at a price of $1.00 per share for gross proceeds of $3,705,000. Among the investors participating in the Offering was FV Pharma Inc., a licensed producer that is working with Cannabis Wheaton Income Corp. (TSX.V:CBW) to develop the world’s largest hydroponic indoor cannabis cultivation facility in Cobourg, Ontario.
Canntab Therapeutics unveils major milestone, with Canada Health approval for its sustained release product
Canntab Therapeutics Ltd (CSE:PILL) has unveiled a major milestone – as the firm along with partner Emblem Corp (CVE:EMC) have received Health Canada approval for research and development activities on oral sustained release formulations of Canntab’s cannabinoids product, sending shares higher.
Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation
PARIS, Ontario, May 14, 2018 (GLOBE NEWSWIRE) — Emblem Corp. (TSX-V:EMC) (TSX-V:EMC.WT) (“Emblem” or the “Company”) and Canntab Therapeutics Limited (CSE:PILL) (“Canntab”) are pleased to announce the receipt of Health Canada approval for research and development activities on oral sustained release formulations of cannabinoids (the “Sustained Release Product” or the “Product”), which are the proprietary products conceived by Canntab representing significant progress in Emblem and Canntab’s partnership to develop long-acting cannabis formulations.